TB-500 (Thymosin Beta-4): What the Research Shows
For laboratory and research use only. This article summarises published scientific research on TB-500 (Thymosin Beta-4). Neurovia’s TB-500 is not intended for human consumption, diagnosis, or treatment of any condition. See our disclaimer.
TB-500 (Thymosin Beta-4): What the Research Shows
TB-500 is a synthetic research peptide analogue of Thymosin Beta-4 — a naturally occurring protein found in virtually all human and animal cells. With a research history spanning several decades, Thymosin Beta-4 and its synthetic analogues have been studied across a broad range of biological contexts, making TB-500 one of the most referenced peptides in preclinical research literature.
This article provides an evidence-based overview of TB-500: its molecular identity, its relationship to the endogenous Thymosin Beta-4 protein, the published research landscape, and its supply format for laboratory use.
What Is TB-500?
TB-500 is the commonly used research name for a synthetic peptide corresponding to amino acids 17–23 of Thymosin Beta-4 — specifically the actin-binding domain of the full-length protein.
The full Thymosin Beta-4 protein is a 43-amino acid polypeptide (sometimes referred to as a small protein or thymosine). TB-500 is a shorter, synthetically produced fragment that corresponds to the region of Thymosin Beta-4 identified in research as the biologically active domain for actin sequestration.
TB-500 sequence (Tβ4 fragment 17–23): Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-OH
(Note: The exact fragment used in commercial research peptides varies by supplier — some supply the full Tβ4 sequence; others supply the LKKTETQ fragment. Buyers should confirm the specific sequence supplied.)
Full Thymosin Beta-4:
- Length: 43 amino acids
- Molecular weight: ~4921 Da
- Gene: TMSB4X
The synthetic TB-500 analogue used in most research peptide contexts is typically the full 43-amino acid sequence or the key actin-binding fragment, supplied at research-grade purity.
Thymosin Beta-4: The Endogenous Context
Thymosin Beta-4 (Tβ4) was first identified and isolated in the 1960s from thymic tissue, initially as part of research into the thymus gland’s role in immune function. The thymosin family of proteins was identified by Allan Goldstein and colleagues at the National Cancer Institute.
Over subsequent decades, Thymosin Beta-4 was found to be one of the most abundant intracellular proteins in mammalian cells, and research interest shifted from its thymic origins toward its role in actin dynamics.
Tβ4 is an actin-sequestering protein. Actin exists in cells in two states: monomeric G-actin (globular) and filamentous F-actin. Thymosin Beta-4 binds to G-actin monomers and regulates their availability for polymerisation into F-actin filaments. This function places Tβ4 at the centre of cell motility, morphology, and cytoskeletal research.
This actin-binding function is the molecular basis from which much of the subsequent TB-500 tissue repair research has been derived.
The Published Research Landscape
Actin Dynamics and Cell Motility
The foundational research on Thymosin Beta-4 concerns its role as an actin-sequestering peptide. Key early work by Safer et al. and Nachmias et al. in the early 1990s established the molecular mechanism of G-actin binding, published in journals including Science and Journal of Cell Biology.
This mechanistic foundation — that Tβ4 regulates actin availability and therefore cell motility — underpins the subsequent research into wound healing, vascular biology, and tissue repair contexts.
Wound Healing and Tissue Repair Research
A substantial body of published research has investigated Thymosin Beta-4 in the context of wound healing and tissue repair in animal models. This work, led significantly by Hynda Kleinman and colleagues at the NIH, has been published across journals including Annals of the New York Academy of Sciences, Journal of Investigative Dermatology, and FASEB Journal.
Studies in rodent models have examined the role of exogenous Tβ4 in contexts including skin wound healing, corneal repair, cardiac tissue, and blood vessel formation — all in preclinical settings.
Cardiovascular Research
Thymosin Beta-4 has attracted significant research interest in the cardiovascular field. Published studies have investigated its role in cardiac tissue contexts, including research examining its interaction with cardiomyocyte survival pathways and vessel formation in ischaemic models.
Notable work includes publications from Deepak Srivastava’s group examining Tβ4 in cardiac regeneration contexts in mouse models, published in journals including Nature.
Musculoskeletal Research
Published preclinical research has examined TB-500 / Thymosin Beta-4 in musculoskeletal contexts — including muscle, tendon, and ligament repair in animal models. This research overlaps with the BPC-157 literature, and some published studies have examined the two peptides in combination in rodent models.
Mechanism of Action: The Actin-Binding Research Basis
The mechanism most consistently supported by the published literature centres on G-actin sequestration:
- Thymosin Beta-4 binds to monomeric G-actin via its LKKTET motif (the key actin-binding domain)
- This sequestration regulates the pool of actin available for polymerisation
- Controlled actin polymerisation is fundamental to cell migration and morphological change
- Cell migration is a prerequisite for wound healing, vascular remodelling, and tissue repair processes
From this mechanistic basis, published research has proposed and investigated downstream effects in various tissue contexts in animal models.
Additional proposed mechanisms include interactions with the ILK (integrin-linked kinase) pathway, explored in publications examining Tβ4’s relationship with cell survival signalling, though this remains an area of ongoing investigation.
TB-500 Half-Life
The half-life of Thymosin Beta-4 and synthetic TB-500 in research contexts is relevant to experimental design. Published pharmacokinetic data on TB-500 specifically is limited; available data primarily relates to the full Thymosin Beta-4 protein.
In published pharmacokinetic studies of Tβ4 in animal models, the peptide demonstrates a relatively rapid plasma clearance. The actin-bound fraction may behave differently from free Tβ4, complicating simple half-life characterisation.
For research protocol design, the limited published pharmacokinetic data should be consulted directly from primary literature rather than relying on anecdotal information. The published research does not provide definitive half-life data for synthetic TB-500 fragments specifically.
TB-500 vs BPC-157: Comparing the Research
These two peptides are frequently referenced together in the preclinical literature and are often studied in combination. Here is how the research contexts compare:
| TB-500 (Thymosin Beta-4) | BPC-157 | |
|---|---|---|
| Origin | Fragment of endogenous Tβ4 protein | Derived from gastric juice protein sequence |
| Length | 43 aa (full Tβ4) or shorter fragments | 15 amino acids |
| Primary mechanism studied | Actin sequestration, cell motility | NO system, growth factor interactions |
| Main research contexts | Wound healing, cardiovascular, musculoskeletal | Gastrointestinal, tissue repair, neurological |
| Research volume | Large — decades of Tβ4 research | Large — primarily Zagreb group publications |
| Endogenous counterpart | Yes — Tβ4 is naturally occurring | No — BPC-157 is fully synthetic |
| Studied in combination | Yes — multiple publications with BPC-157 | Yes — multiple publications with TB-500 |
TB-500 Research Supply Format
For laboratory research, TB-500 is supplied as a lyophilised white to off-white powder in sealed vials.
Neurovia supplies TB-500 in the following research formats:
- TB-500 (Thymosin Beta-4) 10mg vial (lyophilised)
- TB-500 Capsules 500mcg
- BPC-157 / TB-500 Blend Capsules 1mg
- BPC Wolverine series (multi-peptide blends including TB-500 with BPC-157 and optional MGF/KPV)
All supplied at 99% purity, third-party tested, with Certificate of Analysis available.
Storage: lyophilised at -20°C long-term; 2–8°C short-term. Once reconstituted, refrigerate and use within 4 weeks.
Further reading: peer-reviewed research on TB-500 (PubMed).
Frequently Asked Questions
What is TB-500?
TB-500 is a synthetic research peptide analogue of Thymosin Beta-4, a naturally occurring actin-sequestering protein found in most mammalian cells. In research contexts, TB-500 typically refers to a synthetic version of the full Tβ4 sequence or its key active fragment.
What is the difference between TB-500 and Thymosin Beta-4?
Thymosin Beta-4 is the naturally occurring 43-amino acid protein. TB-500 is the synthetic research peptide — either the full 43-amino acid sequence or a shorter fragment corresponding to the actin-binding domain, produced by chemical synthesis to research-grade purity.
What research has been done on TB-500?
Research on Thymosin Beta-4 spans several decades, covering wound healing, cardiovascular biology, musculoskeletal repair, and cell motility contexts in animal models and in vitro. Key research groups include those at the NIH (Kleinman) and various cardiovascular research institutions. TB-500 as a synthetic compound is studied as a functional analogue.
What is the the peptide half-life?
Published pharmacokinetic data specifically for synthetic the compound fragments is limited. Available data on full Thymosin Beta-4 in animal models indicates relatively rapid plasma clearance, though actin-bound fractions may behave differently. Researchers should consult primary pharmacokinetic literature for protocol design.
What is the mechanism of this compound?
The most researched mechanism is G-actin sequestration: Thymosin Beta-4 binds to monomeric G-actin via its LKKTET motif, regulating actin polymerisation, which is fundamental to cell motility and tissue repair processes.
What is the difference between it and BPC-157?
the peptide is a synthetic analogue of an endogenous actin-binding protein, studied primarily in wound healing, cardiovascular, and musculoskeletal research contexts. BPC-157 is a fully synthetic 15-amino acid peptide studied primarily in gastrointestinal and tissue repair contexts. Both have been studied in combination in preclinical animal models.
Is the compound approved for human use?
No. this compound is not approved by the FDA or any major regulatory agency for human therapeutic use. It is a research compound available for laboratory and preclinical research purposes only.
How is it supplied for research?
the peptide is typically supplied as a lyophilised powder in sealed vials at ≥98–99% purity, with a Certificate of Analysis from a third-party laboratory confirming identity and purity.
This article summarises published peer-reviewed research on Thymosin Beta-4 and the compound and is provided for informational purposes only. Neurovia’s this compound is supplied for laboratory research use only and is not intended for human consumption, diagnosis, treatment, or prevention of any condition. Full disclaimer →
Related Reading
For a differently-mechanism tissue peptide studied in parallel research programs, see the research overview on GHK-Cu.